Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting
May 26 2022 - 5:00PM
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage
biopharmaceutical company that is genetically engineering red blood
cells to create an entirely new class of cellular medicines called
Red Cell Therapeutics™ for the treatment of cancer and autoimmune
diseases, today announced that the Company will present a Trials in
Progress poster presentation for its second broad immune
stimulation program, RTX-224, at the American Society of Clinical
Oncology (ASCO) Annual Meeting being held virtually from June 3-7,
2022.
The Trials in Progress poster presentation will summarize the
proposed mechanism of action of RTX-224, preclinical observations
to date and the clinical trial design, including the translational
medicine approach, for the ongoing Phase 1/2 clinical trial of
RTX-224 for the treatment of patients with select advanced solid
tumors, including cutaneous melanoma, head and neck squamous cell
carcinoma, non-small cell lung cancer, triple negative breast
cancer and urothelial cancer.
Poster Title: A Phase 1/2 Study of RTX-224, an
Engineered Red Blood Cell Expressing 4-1BB Ligand and
Membrane-Bound IL-12, for the Treatment of Patients with Select
Advanced Solid Tumors Session Title: Developmental
Therapeutics—ImmunotherapyAbstract Number:
TPS2680Date and Time: Sunday, June 5, 2022,
8:00-11:00 a.m. CDT
About the RTX-224 Phase 1/2 Clinical Trial
This is a Phase 1/2 open label, multicenter, multidose,
first-in-human dose-escalation and expansion study to determine the
safety and tolerability, pharmacokinetics, maximum tolerated dose
and a recommended Phase 2 dose and dosing regimen of RTX-224 in
adult patients with certain relapsed/refractory or locally advanced
solid tumors including non-small cell lung cancer, cutaneous
melanoma, head and neck squamous cell carcinoma, urothelial
(bladder) carcinoma and triple-negative breast cancer. The trial
will also assess pharmacodynamic changes in immune cell populations
relative to baseline and anti-tumor activity. The study will
include a monotherapy dose escalation phase followed by an
expansion phase in specified tumor types during the Phase 2 portion
of the trial.
About RTX-224
RTX-224 is an allogeneic, off-the-shelf cellular therapy product
candidate that is engineered to express hundreds of thousands of
copies of 4-1BB ligand (4-1BBL) and interleukin-12 (IL-12) on the
cell surface. RTX-224 is designed to broadly stimulate the immune
system by activating and expanding NK and CD8+ memory T cells and
is expected to produce a broad and potent anti-tumor T cell
response, an innate immune response and generate anti-tumor
activity in those tumor types with known sensitivity to T cell
killing, including tumor types with high mutational burden, PD-L1
expression and/or known responsiveness to checkpoint
inhibitors.
About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical
company developing a new class of medicines called Red Cell
Therapeutics™. The Company’s proprietary RED PLATFORM® was designed
to biologically engineer and culture Red Cell Therapeutics™ that
are selective, potent and off-the-shelf allogeneic cellular
therapies for the potential treatment of several diseases across
multiple therapeutic areas. Rubius’ initial focus is to advance
RCT™ product candidates for the treatment of cancer and autoimmune
diseases by leveraging two distinct therapeutic modalities — potent
cell-cell interaction and tolerance induction.
Rubius Therapeutics was recently named among the 2021 Top
Places to Work in Massachusetts by the Boston Globe, and its
manufacturing site was recently named 2022 Best Places to
Work in Rhode Island by Providence Business News. For more
information, visit www.rubiustx.com, follow us on Twitter or
LinkedIn or like us on Facebook.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended,
including, without limitation, plans and expectations, and the
potential, for RTX-224, including the RTX-224 Phase 1/2 clinical
trial. The words “may,” “will,” “could,” “would,” “should,”
“expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,”
“predict,” “project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those risks and uncertainties related to the
development of our Red Cell Therapeutic product candidates and
their therapeutic potential, our ability to execute on our plans
and expectations, our analyses of clinical and preclinical data and
other risks identified in our filings with the U.S. Securities and
Exchange Commission (SEC), including our Annual Report on Form 10-K
for the year ended December 31, 2021 and subsequent filings with
the SEC, including our Quarterly Report on Form 10-Q for the
quarter-ended March 31, 2022, and risks and uncertainties related
to the severity and duration of the impact of COVID-19 on our
business and operations. We caution you not to place undue reliance
on any forward-looking statements, which speak only as of the date
they are made. We disclaim any obligation to publicly update or
revise any such statements to reflect any change in expectations or
in events, conditions or circumstances on which any such statements
may be based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements.
Any forward-looking statements contained in this press release
represent our views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent
date.
Contacts: InvestorsLori
Murray, Chief Corporate Affairs Officer
lori.murray@rubiustx.com
Media Marissa Hanify, Director, Corporate
Communicationsmarissa.hanify@rubiustx.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Apr 2024 to May 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From May 2023 to May 2024